Targeting Melanoma-Associated Fibroblasts May Aid in Overcoming Cancer Stem Cell-Driven Drug Resistance

Shao H, Moller M, Le N, Ortiz Y, Velazquez O, Liu Z. Targeting Melanoma-Associated Fibroblasts to Overcome Cancer Stem Cell-Driven Drug Resistance. J Am Coll Surg. February 2026. 

This article explores how melanoma-associated fibroblasts (MAFs) support melanoma progression rather than serving as passive structural cells as previously thought. The authors show that these fibroblasts promote tumor growth, invasion, and resistance to therapy through paracrine signaling, extracellular matrix remodeling, and immunomodulatory effects. 

A central finding is that MAFs secrete growth factors, cytokines, and matrix-modifying enzymes that enhance melanoma cell proliferation and facilitate invasion through the surrounding tissue. This includes promoting angiogenesis and creating a remodeled extracellular matrix that enables tumor spread. 

Importantly, these fibroblasts also contribute to immune evasion by altering the tumor microenvironment in ways that suppress effective anti-tumor immune responses and contributes to an environment that allows the development of resistance to targeted therapeutics.

The article demonstrates the ability to modify melanoma cell resistance to anti-BRAF therapy by changing cell signaling within the tumor stroma and fibroblasts. Following notch activation within the MAFs, melanoma cells in culture were shown to be less resistant to BRAF inhibitors. 

The study helps lay the groundwork for the targeted therapeutics of the tumor stroma and microenvironment and represents promising early work that may help fight the large problem of acquired tumor resistance to therapeutic agents.